In the latest edition of IPSOR’s Value in Health, Ross Maclean takes an in depth look at several novel measures of value beyond QALY and how they may apply to European health technology assessment.
Can the tools we use to measure value keep up with the pace at which oncology is advancing? Explore how four different frameworks have evolved over time and the role they play in oncology value assessment.
Read the full article here.
Perhaps we should take a closer look at how Apple devices and other internet of things (IoT) technologies are impacting the healthcare landscape and have the potential to impact the standard of care (SOC) in many disease states in the future.
Read the full article here.
Machine learning is the subset of AI that is related to the development of algorithms that can make accurate predictions of future outcomes via pattern recognition and rules-based logic. Such use of logic and algorithms can improve patient selection, provide predictive long-term outcomes, and reduce the time and cost in the execution of clinical trials.
Read the full article here.
In the latest edition of Journal of Clinical Pathways, Precision experts Chris Dillon, Chrysanthe Peteros and Larry Blandford examine the expanding role of hub support services in the pharmaceutical marketplace, emphasizing their importance as increasingly complex therapies requiring higher degrees of specialization and flexibility are launched.
Is Real-World Evidence to be trusted? Well-documented data can make a difference to both FDA and formulary decision makers, as described by Precision for Value’s Jeremy Schafer, Senior Vice President, Access Experience and Dan Danielson, Senior Director, Access Experience, writing in Managed Healthcare Executive.
To read the full article please click here.
Precision for Value, Senior Vice President, Director of Value Transformation, Maureen Hennessey brings her personal experience to bear in this important Journal of Clinical Pathwaysˆ article on the social determinants of health—exploring where things stand now and opportunities for improvement.
Read the full article here.
Precision Value & Health recently surveyed 25 key decision makers at leading health plans and delivery networks regarding gene therapy—including who should be treated and when. STAT shares the intriguing results in this article by Jeremy Shafer, Senior VP of Access Experience, Precision for Value. Hint: cost isn’t the only answer.
There are many ways to assess cost—yet as new evidence surfaces about a therapy’s efficacy, original cost assessments may not change. Larry Blandford, Executive VP, Customer Solutions, Precision Value & Health, believes evolving the current assessment model is essential: To address concerns about soaring healthcare cost, focus on value.
Careful planning, improving access to care, and managing pain, depression and side effects are logical paths to better oncology care. Three Precision for Value experts—Larry Blandford, Executive Vice President, Managing Partner; Maureen Hennessey, Senior Vice President, Director of Value Transformation; and Linda Bolland, Senior Advisor, explain how in the Journal of Clinical Pathways.
To read the full article, click here
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
